Go to full publication
Etanercept therapy leads to reductions in matrix metalloproteinase-3 in patients with erosive hand osteoarthritis.
March 1, 2020
Scand J Rheumatol
- Home
-
Publications
Publications
Active filters
Add filters (0)
2 results
CRP and a biomarker of type I collagen degradation, C1M, can differentiate anti-inflammatory treatment response in ankylosing spondylitis.
January 1, 2016
Biomark Med
Abstract AIM To investigate if tissue turnover biomarkers were efficacy biomarkers in ankylosing spondylitis and if the biomarkers at baseline predicted a good outcome (BASDAI50). PATIENTS & METHODS Twenty-two etanercept treated ankylosing spondylitis patients were investigated for inflammation (CRP, ESR, CRPM) and tissue turnover (C1M, C2M, C3M) during the first year of treatment. Biomarkers profiles […]